TORONTO, July 3, 2025 /CNW/ - Vertex Pharmaceuticals (VRTX) (Nasdaq: VRTX) recently announced positive longer-term data for Pr CASGEVY ® (exagamglogene autotemcel) from global ongoing pivotal ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...

Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. Vertex Pharmaceuticals Incorporated Investors: [email protected] ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $345.57 today based on a price of $445.20 for VRTX at the time of writing.

Review Vertex Pharmaceuticals Inc (VRTX:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Review the current valuation for Vertex Pharmaceuticals Inc (VRTX:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Discover real-time Vertex Pharmaceuticals Incorporated Common Stock (VRTX) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with ...

This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals scored a major win with the EU approval of ALYFTREK, expanding its cystic fibrosis treatment access in ...